The company entered a global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3B, including a $700M upfront payment. The large upfront and upside from milestone/option payments are incremental-positive for near-term cash flow and commercialization optionality.
The company entered a global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3B, including a $700M upfront payment. The large upfront and upside from milestone/option payments are incremental-positive for near-term cash flow and commercialization optionality.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
